StockData
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc. (TELO) stock

TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.42−0.00 (-0.61%)

Close on Nov 18, 2026Market cap $28.92MP/E –Yield –

Telomir Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$2.19M–
Q1 FY2024Mar 31, 2024$1.92M–

More Telomir Pharmaceuticals figures

See a number that looks wrong?